New data from the CONFIDENCE trial show that combination therapy with a sodium–glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, and the nonsteroidal mineralocorticoid receptor antagonist, finerenone, resulted in a significantly greater reduction in albuminuria than either treatment alone in patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). These results were presented at the 62nd European Renal Association Congress in Vienna.

Rajiv Agarwal and colleagues randomly assigned 818 patients with CKD and T2DM to combination therapy or monotherapy with empagliflozin or finerenone. All participants also received the maximum tolerated labelled dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. The primary outcome was change in urinary albumin to creatinine ratio (UACR) from baseline to day 180.